Òâ´óÀû¹ó±ö»á¹ÙÍø

²úÆ·ÖÐÐÄ

ÁªÏµÒâ´óÀû¹ó±ö»á¹ÙÍø

+86-010-82156767

ÏúÊÛרÓãº

+86-010-62983737 

+86-15522507305 

+86-15522507319 

+86-15522507326

µØµã£º±±¾©Êк£µíÇøÎ÷С¿Ú·66ºÅÖйش嶫Éý¿Æ¼¼Ô°C-1Â¥Èý²ã

undefined
+
  • undefined

t-Boc Amine PEG Succinimidyl Carboxymethyl Ester

²úÆ·´úºÅ£º

TBOC-PEG-SCM

²úÆ·´¿¶È£º

¡Ý 90%

°ü×°¹æ¸ñ£º

1g, 10g, 100gµÈ£¨ÌØÊâ°ü×°ÐèÊÕÈ¡·Ö×°Óöȣ©

·Ö×ÓÁ¿£º

2000 Da,3500 Da, 5000 Da, 7500 DaµÈ

²úÆ·×Éѯ£º

¿ÆÑпͻ§Ð¡ÅúÁ¿Ò»¼ü²É¹ºµØµã£¨Ð¡ÓÚ5¿Ë£©

Á¢¼´Ïµ¥
  • ²úÆ·ÃèÊö
  • ²Î¿¼ÎÄÏ×

  • ¡¡¡¡Òâ´óÀû¹ó±ö»á¹ÙÍø¿Æ¼¼Éú²úµÄÊ嶡ÑõôÊ°±»ù¾ÛÒÒ¶þ´¼çúçêõ£ÑÇ°·ôȼ׻ùõ¥²úÆ·Öк¬ÓÐÊÜtBoc± £»¤µÄ°·»ùÍÅ£¬Í¨³£ÓÃ×÷Á½ÖÖ²î±ð»¯Ñ§ÎïÖʵĽ»Áª¼Á»ò¼ä¸ôÎï¡£´ËÒ칦ЧPEGÑÜÉúÎïÖеÄPEG²¿·Ö¿ÉÌṩˮÈÜÐÔ¡¢ÉúÎïÏàÈÝÐÔ¼°ÈáÐÔ¡£´Ë²úƷרÃÅÓ¦ÓÃÓÚ¿¹ÌåżÁªÒ©Îï(ADC¡¯s)µÄ¿ª·¢¡£

    ²úÆ·±àÂë

    ²úÆ·´úºÅ

    A5095

    TBOCNH-PEG2000-SCM

    A5056

    TBOCNH-PEG3500-SCM

    A5096

    TBOCNH-PEG5000-SCM

    A5097

    TBOCNH-PEG7500-SCM

    ¡¡¡¡Òâ´óÀû¹ó±ö»á¹ÙÍø¿Æ¼¼ÌṩTBOC-PEG-SCM·Ö×ÓÁ¿2000 Da,3500 Da, 5000 Da, 7500 DaµÄ²úÆ·1¿ËºÍ10¿Ë°ü×°¡£

    ¡¡¡¡Òâ´óÀû¹ó±ö»á¹ÙÍø¿Æ¼¼Ìṩ·ÖװЧÀÍ£¬ÐèÒªÊÕÈ¡·Ö×°ÓöÈ£¬Èç¹ûÄúÐèÒª·ÖװΪÆäËû¹æ¸ñÇëÓëÎÒÃÇÁªÏµ¡£

    ¡¡¡¡Òâ´óÀû¹ó±ö»á¹ÙÍø¿Æ¼¼Í¬Ê±ÌṩÆäËû·Ö×ÓÁ¿µÄTBOC-PEG-SCMÑÜÉúÎï²úÆ·£¬ÈçÄãÐèÒªÇëÓëÎÒ˾sales@jenkem.comÁªÏµ¡£

    ¡¡¡¡Òâ´óÀû¹ó±ö»á¹ÙÍø¿Æ¼¼Ìṩ´óÅúÁ¿Éú²ú²úÆ·¼°GMP¼¶±ð²úÆ·£¬ÈçÐ豨¼ÛÇëÓëÎÒÃÇÁªÏµ¡£

     

  • ¡¡¡¡References:

    ¡¡¡¡1. Kuruvilla, S.P., et al., Effect of N-acetylgalactosamine ligand valency on targeting dendrimers to hepatic cancer cells, International journal of pharmaceutics, 2018, 545(1-2), pp.27-36.

    ¡¡¡¡2. Kuruvilla, S.P., et al., N-Acetylgalactosamine-Targeted Delivery of Dendrimer-Doxorubicin Conjugates Influences Doxorubicin Cytotoxicity and Metabolic Profile in Hepatic Cancer Cells, Adv. Healthcare Mater., 2017, 1601046.3.

    ¡¡¡¡3. Balasso, A., et al., Re-programming pullulan for targeting and controlled release of doxorubicin to the hepatocellular carcinoma cells, European Journal of Pharmaceutical Sciences, 2017.

    ¡¡¡¡4. Lu, J., et al., Targeted Delivery of Doxorubicin by Folic Acid-Decorated Dual Functional Nanocarrier, Mol. Pharmaceutics, 2014, 11(11), p: 4164–4178.

    ¡¡¡¡5. Tanwir, K., et al., Coexisting Phases in PEGylated Phosphocholine Membranes: A Model Study, Langmuir, 2012, 28(39), pp 14000–14009.

    ¡¡¡¡6. Zhang, Y., et al., Incorporation of a selective sigma-2 receptor ligand enhances uptake of liposomes by multiple cancer cells. Int J Nanomedicine, 2012, 7: p. 4473–4485.

    ¡¡¡¡7. Smolensky, E. D., et al., Magnetoluminescent Agents for Dual MRI and Time-Gated Fluorescence Imaging, European Journal of Inorganic Chemistry, 2012, (12): 2141-2147.

    ¡¡¡¡8. Smolensky, E. D., et al., A responsive particulate MRI contrast agent for copper(I): a cautionary tale, Dalton Trans., 2012, 41, 8039-8046.

    ¡¡¡¡9.Chen, Q., et al., Biodegradable nanoparticles decorated with different carbohydrates for efficient macrophage-targeted gene therapy, Journal of Controlled Release, 2020; 323:179-90.

²úƷѯ¼Û

ÍøÕ¾µØͼ